1 / 44

Latent TB infection

Latent TB infection . Dr CC Leung TB & Chest Service Public Health Services Branch Centre for Health Protection Department of Health 香港特別行政區 衞 生署 衞 生防護中心胸肺科. 香港地理及人口. 中國大陸之南部 人口數目 = ~6,800,000 土地面積 = 1098 平方公里 人口密度 = 每平方公里 ~6500 人. 香港的醫療系統. 公營 私營 基層醫療服務 30% 70%

kirti
Download Presentation

Latent TB infection

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Latent TB infection Dr CC Leung TB & Chest ServicePublic Health Services BranchCentre for Health ProtectionDepartment of Health香港特別行政區衞生署 衞生防護中心胸肺科

  2. 香港地理及人口 • 中國大陸之南部 • 人口數目 = ~6,800,000 • 土地面積 = 1098 平方公里 • 人口密度 = 每平方公里~6500人

  3. 香港的醫療系統 公營 私營 基層醫療服務 30% 70% 醫院服務 90% 10%

  4. 香港診治結核病之服務 結核病患者 衞生署 胸肺診所 19 間診所 每年約6,000 症 衞生署 普通科 門診部 醫管局 急症部 基層 私家醫生 醫管局胸肺醫院 主要有5 間醫院 約800 病床 7,000 住院人次 私家醫院 醫管局 專科門診 醫管局 一般醫院 第二層

  5. LTBI: Screen and Treat ? • Disease • Natural History / Impact • Diagnostic / Treatment Tools • Effectiveness / Limitations • Goal of Intervention • Personal protection / Public health control • Cost-effectiveness • Individual level / Community perspective

  6. Latent TB Infection • Infection by the tubercle bacillus is pre-requisite for development of disease • Latent Period • Long and Variable • Asymptomatic and Non-infectious • Provide an opportunity for intervention

  7. From Infection to Disease • Risk of developing disease • Multiple factors related to interaction between pathogen and human host • Lifetime Risk: • About one in ten (average) • The risk is greater initially • 5% within initial 2-5 years • 5% during the rest of lifetime

  8. Predisposing Conditions • HIV infection • Steriod / Immunosuppresant / anti-TNF • Silicosis • Chronic Renal Failure / hemodialysis • Diabetes Mellitus • Underweight • Gastrectomy / Jejunoileal Bypass • Malignancy / Debilitated State • Alcoholism / Smoking / Injection Drug Use

  9. Active TB Disease - 2003 WHO Fact sheet N°104 (Revised April 2005)

  10. Can we wait until disease ? • Airborne spread • major challenge in control • Nonspecific symptoms • delay in diagnosis • Serious forms • grave consequences • High bacilli load • mutation and resistance

  11. Diagnostic tools • Traditional standard • Tuberculin test • Newer interferon-γrelease test • T Spot-TB®(Oxford Immunotec) • QuantiFERON®-TB Gold (Cellestis)

  12. Tuberculin test • Intradermal injection preferred for better standardization • 2 units of PPD-RT23 (equivalent to 5 units of PPD-S)

  13. Largest transverse diameter of induration read between 48-72 h

  14. Specificity (TST) • PPD contains a mixture of proteins • not entirely specific to the tubercle bacillus • potential cross-reactivity with other mycobacterial species • Positive reaction can occur with: • Active disease / Latent Infection • BCG vaccination / Booster • Other mycobacterial species

  15. BCG Vaccination(HK) • BCG vaccination • First introduced in April 1952 • Neonatal vaccination • 99% coverage since 1970’s • Revaccination • Stopped only in 2000

  16. Sensitivity (TST) • Exact sensitivity for latent TB infection uncertain in absence of gold standard • Around 80%-90% sensitivity in active TB cases, • Varies with strength of tuberculin / cut-off point • Trade-off between sensitivity and specificity • False negative can also occur with a number of other conditions

  17. False-negative (TST)

  18. Predictive values (TST)

  19. Interferon-γRelease Test • Earlier version: • Measures the production of interferon- (IFN-) in T-lymphocytes upon stimulation with PPD. • Newer assays: • PPD is replaced by ESAT-6 and CFP10 (specific for MTB and not present in BCG and most MOTT)

  20. QuantiFERON® -TB Gold • Whole blood assay • Stimulate lymphocytes • in fresh whole blood • with ESAT-6 and CFP10 • Measure IFN- level by • Enzyme-linked immunosorbent assay • Cell isolation not required • Variable background response: • Cut-off value may not be too sharp • Approved by FDA, USA in May 2005

  21. T Spot-TB® • ELISPOT test • Isolation of lymphocytes from fresh blood • Incubation with ESAT-6 and CFP10 • Enzyme-Linked ImmunoSPOT assay • For INF--producing T-lymphocytes • More tedious, but may be more sensitive • Approved for use in Europe

  22. Sensitivity and Specificity • Estimation is difficult • No gold standard for latent TB infection • Estimate of Sensitivity • positive rate in bacteriologically confirmed TB • 45/47 (Elispot, Lavani 2001) • Estimate of specificity • negative rate in BCG vaccinated subjects without risk factor for exposure • 26/26(Elispot, Lavani 2001) Lavani et al, Lancet 2001;23:2017-21

  23. ELISPOT vs TST(School Outbreak, UK) • Good Agreement • 89% concordance, kappa=0·72, p<0·0001 • ELISPOT correlated better with • proximity (p=0·03) • duration of exposure (p=0·007) • TST more likely to be positive • in BCG-vaccinated vs unvaccinated (p=0·002) • ELISPOT results • Not associated with BCG vaccination (p=0·44). Ewer K, et al. Lancet 2003; 361: 1168–73

  24. Potential advantages • Higher sensitivity • ?Help rule out infection / disease • More specific (specific antigens) • ?Help to rule in infection / disease • No booster effect on repeated testing • Good for serial surveillance • One clinic visit instead of two: • May facilitate uptake

  25. Limitations • Require prompt delivery of fresh blood • Technically much more demanding • Currently much more expensive • Test for infection rather than disease • Clinical experience is limited at this stage • Changes with time after exposure and treatment • Not fully evaluated in terms of the risk of disease development

  26. Treatment of LTBI • Single drugs or simple combinations of two drugs • Isoniazid for 6 to 12 months • 5mg/kg daily (maximum 300mg) • 15mg twice weekly (maximum 900mg) (US) • Alternative regimens • Rifampicin for 4 months (US) • Isonoazid and Rifampicin for 3 months (Europe)

  27. Hepatotoxicity • Notwithstanding the use of only one or two drugs, hepatotoxicity remains an important side effect • While untreated active TB often kills, only one out of ten latently infected subjects will actually develop disease. • Caution is therefore required in subjecting these asymptomatic individuals to treatment.

  28. Possible Approaches • Population Approach: • All infected individuals within the community • Targeted Approach: • High risk of Disease / Grave Consequence

  29. Factors for Consideration • Goal of intervention • Personal Protection / Public Health Control • Cost-effectiveness • Prevalence of infection / Risk of Disease • Limitations of Diagnostic / Treatment Tools

  30. TB Notification Rate (Hong Kong)

  31. Reactivation vs Recent Transmission TB cases Progressive primary * Exogenous reinfection * Endogenous reactivation # 1950 2000 Year Ageing of the TB epidemic

  32. Aging of the TB Epidemic • Population-based IS6110-based RFLP study • 24.5% (of 691 isolates) belonged to clusters • Recent transmission: 15 to 20% • Endogenous reactivation • Treat active disease by DOTS • Control recent transmission But • Little impact on endogenous reactivation Chan-Yeung M, et al. J Clin Microb 2003;41:2706-8

  33. Population Approach • Treatment of latent TB reduces endogenous reactivation • Can we treat every infected one to eliminate TB from our population?

  34. Estimated Infection Rate (HK) *Estimation based on: Incidence (smear-positive cases) = ARI * Styblo ratio

  35. TST Profile (HK Primary Students 1999)

  36. Number to Treat ( HK Primary Students) Leung CC et al. Risk of TB among school children in Hong Kong. Arch Ped Adol Med, in press

  37. Targetted Approach (HK) • High-risk groups: • Recent Contacts • HIV • Silicosis • Immunosuppressive Treatment / Anti-TNF

  38. Household Contacts ( HK 2002-2003)

  39. Recent vs Remote Infection • Remote infection • Much lower risk of disease • Increases with age • Interferon-γrelease test • More specific BUT • May not differentiate between recent and remote Infection

  40. Predictive Value of Positive Testfor Recent Infection / Reinfection Assume: 100% sensitivity & specificity; 20% recent transmission

  41. Targetted Approach: Impact • Personal protection • More cost-effective than population approach • Limited Impact on TB control • Prevent few cases, e.g. Close contacts • Initial screening: • Only 2% of all notifications locally • Not directly preventable as already disease • Later 5 years: only another 4% at best

  42. Looking into Future • Researches and Development: • Better characterization of disease risk • Newer diagnostic tools • Simpler, and more affordable • Better ability to predict actual disease risk • Better treatment regimen • Shorter, safer and more effective • Affordable and Acceptable for wide application

  43. Thank You

More Related